Evogene (EVGN) Notes Payables (2023)

Evogene (EVGN) posted Notes Payables of $393000.0 for Q4 2023, down 20.45% sequentially from $494000.0 in Q3 2023.

Evogene (EVGN) Notes Payables (2023) Analysis & Trends

Evogene has reported Notes Payables for 1 years, with the latest figure at $393000.0 in Q4 2023.

Quarterly Notes Payables changed N/A year-over-year to $393000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $393000.0 (changed N/A YoY) and the FY2023 annual result came in at $393000.0, changed N/A from the prior year.
Notes Payables eased to $393000.0 in Q4 2023 per EVGN's latest filing, from $494000.0 in the prior quarter.
Over five years, Notes Payables peaked at $578000.0 in Q2 2023 and troughed at $393000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Evogene	4.38 Mn	4.38 Mn	204,000.00

Download Data